Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

LLM 2021 | Cold and warm autoimmune hemolytic anemia

Catherine Broome • 13 Oct 2021
LLM 2021
Anemias

Catherine Broome, MD, Lombardi Cancer Center, Washington, DC, gives an update on autoimmune hemolytic anemias. Warm autoimmune hemolytic anemia accounts for around 80% of all autoimmune hemolytic anemias, and it’s mediated by an IgG autoantibody. While cold autoimmune hemolytic anemia is less common, accounting for about 15-18% of cases, and it’s mediated by an IgM autoantibody that subsequently, after binding to the antigen on the surface of the red blood cell, activates the classical pathway of complement, which is responsible for hemolysis. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.

Disclosures

Sanofi, Argenx, Rigel, Alexion, Annexon, Cellphire

More from Catherine Broome

Unmet needs in the treatment and management of cold agglutinin disease
1:50
Unmet needs in the treatment and management of cold agglutinin disease
Catherine Broome • 18 Dec 2023
Targeting the complement cascade in autoimmune hemolytic anemias
1:30
Targeting the complement cascade in autoimmune hemolytic anemias
Catherine Broome • 18 Dec 2023
Sutimlimab in cold agglutinin disease: a post-hoc analysis of safety data from CARDINAL & CADENZA
1:59
Sutimlimab in cold agglutinin disease: a post-hoc analysis of safety data from CARDINAL & CADENZA
Catherine Broome • 18 Dec 2023
Time to achieve platelet count response with efgartigimod in patients with persistent/chronic ITP
2:50
Time to achieve platelet count response with efgartigimod in patients with persistent/chronic ITP
Catherine Broome • 18 Dec 2023

Related Videos

Managing ruxolitinib-associated anemia in myelofibrosis: dose reduction and add-on therapies
1:48
Managing ruxolitinib-associated anemia in myelofibrosis: dose reduction and add-on therapies
Ciro Rinaldi • 10 Sep 2026
Beyond JAK inhibitors: emerging approaches to anemia management in myelofibrosis
4:29
Beyond JAK inhibitors: emerging approaches to anemia management in myelofibrosis
Prithviraj Bose • 18 Sep 2026
Distinguishing disease- and treatment-related anemia in myelofibrosis
1:42
Distinguishing disease- and treatment-related anemia in myelofibrosis
Aaron Gerds • 21 Sep 2026
Insights into the evolving treatment paradigm for myelofibrosis beyond spleen and symptom control
1:16
Insights into the evolving treatment paradigm for myelofibrosis beyond spleen and symptom control
Haifa Kathrin Al-Ali • 13 Jun 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals